Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection

Abstract

Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virologic suppression could be achieved or maintained in patients with baseline or acquired M184V/I mutation, doubts exists about its use. This report presents a patient living with human immunodeficiency virus infection who had no resistance test results available, had heavy treatment experience, and maintained viral suppression following switching to DTG + 3TC dual therapy.

Keywords

• dolutegravir
• lamivudine
• dual antiretroviral treatment